BioRay Professional Service Team

We’re here to help! Please choose the service you need.：

Customer Service Hotline

Have questions about health supplements or daily skincare?

0800-200-026

Testing Inquiry

Want to learn more or book your personalized test?

06-505-2755

ODM/OEM

Looking for Health Supplement ODM/OEM Partnerships?

08-762-6868

Service Hours: Monday – Friday, 8:30 AM – 5:30 PM

Testing - Oncology Profile

Oncology Profile

Cancer Risk Assessment—Early Detection, Seizing Prevention Opportunities

Why Is "Precision" Cancer Risk Assessment Needed?

 

Cancer development results from multifactorial interactions, from genetic susceptibility and environmental exposure to lifestyle habits—every factor can influence risk.
Traditional cancer screening (such as imaging tests, tumor markers) often only detects cancer after cells have developed to a certain stage, missing the golden window for early prevention.
BioRay's "Cancer Risk Assessment" places "preventive medicine" at its core, breaking free from single-test limitations to deeply analyze your genes and metabolites at the molecular level,
tracking circulating cell-free DNA (cfDNA) levels in your blood to provide risk warnings before disease takes root.

Cancer Risk Assessment—Early Detection, Seizing Prevention Opportunities

Why Is "Precision" Cancer Risk Assessment Needed?

 

Cancer development results from multifactorial interactions, from genetic susceptibility and environmental exposure to lifestyle habits—every factor can influence risk.
Traditional cancer screening (such as imaging tests, tumor markers) often only detects cancer after cells have developed to a certain stage, missing the golden window for early prevention.
BioRay's "Cancer Risk Assessment" places "preventive medicine" at its core, breaking free from single-test limitations to deeply analyze your genes and metabolites at the molecular level,
tracking circulating cell-free DNA (cfDNA) levels in your blood to provide risk warnings before disease takes root.  

 

 (CTC)

 

 

 

 

Our Differentiated Advantages and Professional Assurance

1. Integrated Application of Six Technology Platforms
Rather than relying on a single technology, we combine platforms such as "Next-Generation Sequencing (NGS)," "Liquid Chromatography-Mass Spectrometry (LC-MS/MS)," and "Real-Time Fluorescence Nucleic Acid Quantification System (qPCR)" to collect data from multiple dimensions—genetics, metabolism, and cellular signals—building a three-dimensional risk assessment model that avoids information gaps from single tests.

 

2. Integrated Genetic and Metabolic Interpretation
We not only analyze cancer-related gene mutations (such as specific oncogenes) and ALDH2 gene rs671 site variations (affecting alcohol metabolism and related disease risks) but also analyze urinary metabolites, cross-validating "innate genetic susceptibility" with "acquired metabolic performance" for more precise risk assessment.